Press release
ER+/ HER2 -ve Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects
Key Takeaways from the ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report
* DelveInsight's ER+/ HER2 -ve Breast Cancer pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for ER+/ HER2 -ve Breast Cancer treatment.
* The leading ER+/ HER2 -ve Breast Cancer Companies such as BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
* Promising ER+/ HER2 -ve Breast Cancer Therapies such as G1T48, Palbociclib, and others.
Request a sample and discover the recent advances in ER+/ HER2 -ve Breast Cancer @ ER+/ HER2 -ve Breast Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
ER+/ HER2 -ve Breast Cancer Overview
HR+ breast cancers are those that express estrogen receptors (ER) or progesterone receptors (PR) or both. These tumors account for 70-80% of all breast cancers. These hormone-dependent cancers can often be treated successfully with a variety of drugs that modulate ER or reduce estrogen. HER2 is short for human epidermal growth factor receptor. HER2 is sometimes called ERBB2, which stands for Erb-B2 receptor tyrosine kinase. HER2 is a gene that produces HER2 proteins, or receptors. If breast cancer cells don't have abnormal levels of HER2 proteins, the breast cancer is considered HER2-negative.
ER+/ HER2 -ve Breast Cancer Emerging Drugs Profile
* AZD9833: Astrazeneca
AZD-9833 acts as selective estrogen receptor degraders. It is being developed as combination therapy with palbociclib (a CDK4/6 inhibitor). It is currently in Phase III stage of dvelopement and is being developed by Astrazeneca.
* BGB-290: BeiGene
Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated for the treatment of HER2 Negative Breast Cancer. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies. It is currently in Phase II stage of development for HER2-Negative Breast Cancer and is being developed by Beigene.
Learn more about ER+/ HER2 -ve Breast Cancer in clinical trials @ ER+/ HER2 -ve Breast Cancer Drugs [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
ER+/ HER2 -ve Breast Cancer Therapeutics Assessment
There are approx. 40+ key companies which are developing the ER+/ HER2-VE Breast Cancer. The ER+/ HER2 -ve Breast Cancer companies which have their ER+/ HER2-VE Breast Cancer drug candidates in the most advanced stage, i.e. Phase III include, Astrazeneca.
DelveInsight's ER+/ HER2 -ve Breast Cancer pipeline report covers around 50+ products under different phases of clinical development like
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage products (Phase I/II and Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Discover more about ER+/ HER2 -ve Breast Cancer in development @ ER+/ HER2 -ve Breast Cancer Clinical Trials [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
ER+/ HER2 -ve Breast Cancer Companies
BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
ER+/ HER2-VE Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravaginal
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
ER+/ HER2 -ve Breast Cancer Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
To know more about ER+/ HER2 -ve Breast Cancer, visit @ ER+/ HER2 -ve Breast Cancer Segmentation [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the ER+/ HER2 -ve Breast Cancer Pipeline Report
* Coverage- Global
* ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* ER+/ HER2 -ve Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* ER+/ HER2 -ve Breast Cancer Companies- BeiGene, H3 Biomedicine, AstraZeneca, Olema Pharmaceuticals, CytomX Therapeutics, Roche, G1 Therapeutics, Sanofi, Jiangsu HengRui Medicine, and others.
* ER+/ HER2 -ve Breast Cancer Therapies- G1T48, Palbociclib, and others.
For further information on the ER+/ HER2 -ve Breast Cancer Pipeline Therapeutics, reach out @ ER+/ HER2 -ve Breast Cancer Products Development [https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* ER+/ HER2-VE Breast Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* AZD9833: Astrazeneca
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* BGB-290: BeiGene
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* OP-1250: Olema Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* ER+/ HER2-VE Breast Cancer Key Companies
* ER+/ HER2-VE Breast Cancer Key Products
* ER+/ HER2-VE Breast Cancer- Unmet Needs
* ER+/ HER2-VE Breast Cancer- Market Drivers and Barriers
* ER+/ HER2-VE Breast Cancer- Future Perspectives and Conclusion
* ER+/ HER2-VE Breast Cancer Analyst Views
* ER+/ HER2-VE Breast Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=er-her2-ve-breast-cancer-pipeline-analysis-2024-clinical-trials-fda-ema-pmda-approvals-emerging-therapies-and-growth-prospects]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ER+/ HER2 -ve Breast Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals, Emerging Therapies, and Growth Prospects here
News-ID: 3526032 • Views: …
More Releases from ABNewswire
SK Law Office's H.E. Samantha Yem Calls on ASEAN Leaders to Place Health Justice …
H.E. Samantha Yem, Founder and President of SK Law Office and Advisor to the Royal Government of Cambodia, today urged ASEAN governments to make health justice a central pillar of national development, delivering a keynote address at the Knowledge Lab for Innovation Community (KLIC) 2025 in Hanoi.
"Health justice is not charity - it is a legal protection owed to every person," Yem said. "No nation can achieve sustainable prosperity with…
SSR Law Offices Announces Expanded Estate Planning, Probate, and Elder Law Servi …
Image: https://www.abnewswire.com/upload/2025/12/a143235c9b32aae5001db3f7f22f6eb6.jpg
NOVI, MI - SSR Law Offices, a highly regarded legal firm serving families across Metro Detroit, is pleased to announce the expansion of its comprehensive Estate Planning, Probate Law, and Elder Law services in Novi, Michigan. This expansion allows residents of Novi and the surrounding communities to access reliable legal guidance focused on long-term security, asset protection, and compassionate support during life's most important transitions.
SSR Law Offices is known…
How to Avoid the Most Frequent Kitchen Remodeling Errors
A kitchen remodel can transform a home, but simple oversights can lead to costly, long-term problems. The following report outlines the most common kitchen design mistakes homeowners make, along with guidance on how to prevent them.
Why Kitchen Design Mistakes Are More Costly Than You Think
A kitchen remodel [https://grandfinishinc.com/services/kitchen-remodeling/]affects daily routines, long-term home value, and overall functionality. When planning begins without a clear understanding of design fundamentals, even a stunning kitchen…
Author Audrey McGrath is introducing her debut children's book, Little Miss Ball …
Joey isn't on the team, but the ballpark is still her favorite place to be. While her brothers play baseball, she discovers that the sidelines have their own kind of magic. Little Miss Ballpark shows that happiness is not only found in home runs and trophies but also in making memories, finding friends, and creating your own sense of belonging.
At home, Joey loves dancing, coloring, and picking out her clothes.…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
